NDA 021978/S-016

SUPPLEMENT APPROVAL

Almirall, LLC
Attention: Jane Yi
Associate Director, Regulatory Affairs
707 Eagleview Blvd., Suite 200
Exton, PA 19341

Dear Ms. Yi:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 17, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Verdeso (desonide) Foam, 0.05%.

This Prior Approval supplemental new drug application provides for changes to the labeling design and layout for the carton and container labels.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021978/S-016.**" Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Yajun Jason Tu, Regulatory Business Process Manager, at (240) 402 - 4202.

Sincerely,

{See appended electronic signature page}

David Lewis, Ph.D.
Branch Chief, BII
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Carton and Container Labeling

David Lewis

Digitally signed by David Lewis
Date: 3/30/2020 02:26:50PM
GUID: 508da72000029f287fa31e664741b577